Scholarlink

Objectives <p>We aimed to compare the clinical course of adult and pediatric patients with new-onset refractory status epilepticus (NORSE), including study of the timing of initiation of immunotherapy timing, duration of intensive care unit (ICU) stay, and functional outcomes.</p> Methods <p>A retrospective review was conducted of patients with NORSE admitted to McGill University Health Centre (January 2013–July 2023). Data collected included demographics, diagnostics, treatments, ICU stay length, long-term anti-seizure medication use, and modified Rankin Scale (mRS) scores, with good outcomes defined as mRS 0–2 and poor outcomes as 3–6. Early initiation of immunotherapy was defined as administration of first-line agent within 7&#xa0;days of admission and second line agent within 30&#xa0;days. Comparisons were made between adult and pediatric patients.</p> Results <p>15 patients were identified (10 adult, 5 pediatric) with median ages of 34 and 4&#xa0;years, respectively. A causative etiology was identified in three adult patients (two anti-NMDA receptor encephalitis, one small cell lung cancer) and two pediatric patients (one anti-NMDA receptor encephalitis and one hemophagocytic lymphohistiocytosis); the remainder were considered to have cryptogenic NORSE. Good functional outcomes (mRS 0–2) were seen in 80% of the pediatric cohort but only 40% of adults. Children that had earlier escalation of chronic immunosuppression tended to have better functional outcomes, though the same trend was not seen in the adult cohort.</p> Discussion <p>There are likely differences in presentation and clinical course between adult and pediatric patients with NORSE, with children possibly having a better long-term prognosis; however, further study is needed. Investigation into age-specific factors may guide more targeted therapeutic approaches. Ideally, a prospective multicenter randomized controlled trial would be conducted in order to generate more robust data to help determine optimal treatment protocols for NORSE across all age groups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative analysis of new-onset refractory status epilepticus in adult and pediatric patients: immunotherapy timing and functional outcomes

  • 期刊论文

  • 发表日期：

    2025年4月18日

查看全文
  • Lubna M. Halawani,
  • Kenneth A. Myers

摘要

Objectives

We aimed to compare the clinical course of adult and pediatric patients with new-onset refractory status epilepticus (NORSE), including study of the timing of initiation of immunotherapy timing, duration of intensive care unit (ICU) stay, and functional outcomes.

Methods

A retrospective review was conducted of patients with NORSE admitted to McGill University Health Centre (January 2013–July 2023). Data collected included demographics, diagnostics, treatments, ICU stay length, long-term anti-seizure medication use, and modified Rankin Scale (mRS) scores, with good outcomes defined as mRS 0–2 and poor outcomes as 3–6. Early initiation of immunotherapy was defined as administration of first-line agent within 7 days of admission and second line agent within 30 days. Comparisons were made between adult and pediatric patients.

Results

15 patients were identified (10 adult, 5 pediatric) with median ages of 34 and 4 years, respectively. A causative etiology was identified in three adult patients (two anti-NMDA receptor encephalitis, one small cell lung cancer) and two pediatric patients (one anti-NMDA receptor encephalitis and one hemophagocytic lymphohistiocytosis); the remainder were considered to have cryptogenic NORSE. Good functional outcomes (mRS 0–2) were seen in 80% of the pediatric cohort but only 40% of adults. Children that had earlier escalation of chronic immunosuppression tended to have better functional outcomes, though the same trend was not seen in the adult cohort.

Discussion

There are likely differences in presentation and clinical course between adult and pediatric patients with NORSE, with children possibly having a better long-term prognosis; however, further study is needed. Investigation into age-specific factors may guide more targeted therapeutic approaches. Ideally, a prospective multicenter randomized controlled trial would be conducted in order to generate more robust data to help determine optimal treatment protocols for NORSE across all age groups.